Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839038 | 0.83 | FAAH (0.53) | FAAHKDM4ECXCR4ALDH1A1POLB | |
| SCHEMBL29462386 | 0.80 | FAAH (0.54) | FAAHKDM4ECXCR4ALDH1A1MEN1 | |
| SCHEMBL31372331 | 0.80 | CXCR4 (0.77) | FAAHKDM4ECXCR4ALDH1A1MEN1 | |
| SCHEMBL5253618 | 0.80 | FAAH (0.54) | FAAHKDM4ECXCR4DRD2DRD3 | |
| SCHEMBL5255062 | 0.80 | FAAH (0.54) | FAAHKDM4ECXCR4ALDH1A1MEN1 | |
| SCHEMBL465778 | 0.80 | CXCR4 (0.77) | FAAHKDM4ECXCR4ALDH1A1MEN1 | |
| SCHEMBL3853383 | 0.80 | CXCR4 (0.65) | FAAHCXCR4ALDH1A1MEN1KMT2A | |
| SCHEMBL28021131 | 0.78 | FAAH (0.49) | FAAHKDM4ECXCR4ALDH1A1DRD2 | |
| SCHEMBL840048 | 0.78 | KMT2A (0.59) | FAAHKDM4ECXCR4ALDH1A1NPC1 | |
| SCHEMBL5346199 | 0.78 | FAAH (0.52) | FAAHKDM4ECXCR4ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| EP-2373639-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063666-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | FAAH 801/4885KDM4E 2573/4885CXCR4 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.